The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Clinical and Translational Science Award (U54 Clinical Trial Optional)
The purpose of this funding opportunity announcement (FOA) is to invite applications to participate in the Clinical and Translational Science Award (CTSA) Program which supports high quality translational science and clinical research locally, regionally and nationally and fosters innovation in research methods, training, and career development.
Only one application per institution is allowed.
- Duke Internal: Interested applicants should contact Paul Noe as early as possible
- Letter of Intent Due Date(s): 30 days prior to the application due date
- Application Due Date(s): January 25, 2019, April 15, 2019, August 15, 2019, December 16, 2019, April 15, 2020, August 17, 2020, December 15, 2020, April 15, 2021, July 15, 2021
PAR-18-940 Expiration Date New Date July 16, 2021 per issuance of NOT-TR-20-036. (Original Expiration Date: August 16, 2021)
Areas of Interest
It is expected that any UL1 award PD(s)/PI(s) will be an established clinician/scientist who reports directly to an official with broad trans-institutional authority, and who personally has the authority and influence necessary to successfully promote translational and clinical research locally, to partner with internal and external stakeholders, support the CTSA Program activities as described below, and fully integrate the hub into the CTSA Program nationally. This may include authority, perhaps shared with other high level institutional officials, over requisite space, protected time, promotions, institutional review boards, contracting, budgeting for clinical research, and staff qualification and certification. In loosely coupled organizations that consist of university and hospital units, the CTSA Program PDs/PIs should have the authority or influence, personally or on their leadership team, to integrate these independent parts of the organization toward CTSA Program goals. If the PD/PI oversees the institution's business office, a plan on how potential conflicts of interest will be managed must be developed.
The CTSA Program PDs/PIs are expected to commit at least two person months and preferably three to six person months effort on the UL1 award annually. For CTSA Programs with multiple PD/PIs, each PD/PI must contribute at least two person months effort. The UL1 PD(s)/PI(s) may not be a PD/PI on a KL2 or TL1 award. Those with designated responsibility for defined areas of the CTSA Program should, in general, possess the knowledge, leadership, and administrative skills and capabilities necessary to direct those programs locally and to speak for the CTSA Program hub in national forums.
Award budgets for the sum of UL1 and KL2 awards are limited to between $3M and $7.5M in direct costs. Within that range, support is limited to 2.5% of total institutional NIH funding in the fiscal year prior to the time of application. Budgets for the TL1 awards are based on the size of the hub, defined as the U plus the K components, and are considered separately. See Administrative Core – Budget Section for details.
The project period is limited to five years.